title: Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus.
abstract: The antiviral activity of a novel biological response modifier (murabutide MDP derivative) has been investigated in 3-week-old OF1 mice infected with influenza (A/Texas/1/77) virus. In each experimental and control group, 10 mice were infected intranasally with a viral dose producing 50% mortality in 5 days and received murabutide via the subcutaneous or intranasal route at various doses either in a simple or in daily repeated administration. All experiments were done in triplicate. Significant prophylactic or therapeutic effects were observed when murabutide was administered the same day as virus, 4 days or 2 days before virus, and 2 days later. These effects varied with the route of administration and the doses of the compound.
authors.affiliation: Laboratoire de Virologie, Université C. Bernard Lyon I, France.
authors.forename: J J
authors.initials: JJ
authors.lastname: Chomel
authors.forename: N
authors.initials: N
authors.lastname: Simon-Lavoine
authors.forename: D
authors.initials: D
authors.lastname: Thouvenot
authors.forename: M
authors.initials: M
authors.lastname: Valette
authors.forename: J
authors.initials: J
authors.lastname: Choay
authors.forename: L
authors.initials: L
authors.lastname: Chedid
authors.forename: M
authors.initials: M
authors.lastname: Aymard
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000281:Administration, Intranasal; D000818:Animals; D004305:Dose-Response Relationship, Drug; D053122:Influenza A Virus, H3N2 Subtype; D009980:Influenza A virus; D007279:Injections, Subcutaneous; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*
chemical_list: D000119:Acetylmuramyl-Alanyl-Isoglutamine; C033575:murabutide